Cyberonics Not Banking On Expanded VNS Therapy Coverage In 2006
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics projects no further coverage decisions in 2006 for its VNS Therapy for treatment-resistant depression (TRD) and has lowered its revenue projections accordingly
You may also be interested in...
Cyberonics Seeks Coverage For Anti-Depression Implant In Select Patients
Cyberonics is pursuing national coverage of its VNS Therapy implant for treatment-resistant depression in a select group of patients, despite continued payor skepticism as to the technology's effectiveness
Cyberonics Seeks Coverage For Anti-Depression Implant In Select Patients
Cyberonics is pursuing national coverage of its VNS Therapy implant for treatment-resistant depression in a select group of patients, despite continued payor skepticism as to the technology's effectiveness
Neurostim Treatment Shows Promise As Psychiatric Treatment, Doc Says
Implanting a device to stimulate the nervous system with electrical current promises to be as viable a treatment for psychiatric conditions as it has proven for movement disorders, according to Ali Rezai, MD, chair of the Cleveland Clinic Center for Neurological Restoration